Journal: Theranostics
Article Title: Inactivating IL34 promotes regenerating muscle stem cell expansion and attenuates Duchenne muscular dystrophy in mouse models
doi: 10.7150/thno.83817
Figure Lengend Snippet: IL34-Igfbp5 axis-mediated SC function through upregulation of PI3K-AKT activity. (A) Left panel, immunoblot analysis of relative protein levels of p-AKT, total AKT and unrelated β-tubulin in 1-day differentiated WT and IL34-KO cultures. Right panel, relative p-Akt protein levels in 1-day differentiated WT and IL34-KO cultures. ***p<0.001. (B) Left panel, western blot analysis of p-AKT, total AKT, and unrelated β-tubulin protein levels in 1-day differentiated IL34-depleted SCs stably infected with shScr or shIgfbp5 lentivirus. Right panel, relative p-Akt protein levels in 1-day differentiated IL34-depleted SCs stably infected with shScr or shIgfbp5 lentivirus. **p<0.01. (C) Left panel, western blot analysis of p-AKT, total AKT, and unrelated β-tubulin protein levels in 1-day differentiated WT SCs treated with BSA or recombinant Igfbp5. Right panel, relative p-Akt protein levels in 1-day differentiated WT SCs treated with BSA or recombinant Igfbp5. *p<0.05. (D) Left panel, western blot analysis of p-AKT, AKT and unrelated β-tubulin protein levels in proliferating myoblasts and 1-day differentiated myoblasts from WT mice. Right panel, relative p-Akt protein levels in proliferating myoblasts and 1-day differentiated myoblasts from WT mice. ***p<0.001. (E) Left panel, immunoblot analysis of the relative protein levels of p-AKT, total AKT and unrelated β-tubulin in 1-day differentiated WT SCs treated with DMSO or LY294002 for 24 h. Right panel, relative p-Akt protein levels in proliferating myoblasts and 1-day differentiated WT SCs treated with DMSO or LY294002 for 24 h. **p<0.01. (F) FACS-isolated SCs were first plated in growth medium to expand and then switched to differentiation medium plus DMSO or LY294002 when cells were 70% confluent. Representative immunofluorescence analysis of MyoG and DAPI costaining in WT SC cultures treated with DMSO or LY294002. Scale bar: 30 μm. (G) Quantification of the percentage of differentiated MyoG cells from differentiated WT SCs treated with DMSO or LY294002. **p<0.01. (H) Representative overlapping images of DMSO- or LY294002-treated differentiated WT SCs stained against MyoD, Ki67 and DAPI. Scale bar: 30 μm. (I) Quantification of the frequency of MyoD + Ki67 - cells from WT SCs in differentiation medium supplemented with DMSO or LY294002. **p<0.01. (J) Representative merged photomicrographs of Pax7-stained WT SCs cultured in differentiation medium containing DMSO or LY294002. Nuclei were labeled with DAPI. Scale bar: 30 μm. (K) Frequency of undifferentiated Pax7 + cells in WT SCs cultured in differentiation medium containing DMSO or LY294002. *p<0.05. (L) Representative immunofluorescence analysis of WT SCs cultured in differentiation medium containing DMSO or LY294002. MyHC and Ki67 were stained to visualize the differentiation index, and DNA was stained with DAPI. Scale bar: 30 μm. (M) Measurement of the differentiation index detected by calculating the percentage of nuclei in MyHC-positive cells. ***p<0.001. (N) LY294002 hindered AKT activity in skeletal muscle regeneration. The beginning of LY294002 treatment was on the 5 th day after injury via intramuscular injection, the later injection was performed every 2 days via intraperitoneal injection, and samples were collected 1 day after the fifth LY294002 treatment. (O) Representative H&E-stained transverse sections of TA muscle from WT mice treated with vector or LY294002 at 14 days postinjury. Scale bar: 50 μm. (P) Quantification of the average CSA of myofibers with centralized nuclei. ***p<0.001.
Article Snippet: After one day in differentiation medium, the medium was supplemented with 100 ng/ml recombinant IL34 (Origene); the same volume of 0.1% BSA was used as a control.
Techniques: Activity Assay, Western Blot, Stable Transfection, Infection, Recombinant, Isolation, Immunofluorescence, Staining, Cell Culture, Labeling, Injection, Plasmid Preparation